Sturge-Weber Syndrome Clinical Trial
Official title:
Longitudinal Neuroimaging in Sturge-Weber Syndrome
In this project the accuracy of a novel, rapid magnetic resonance imaging (MRI) approach to detect brain abnormalities in patients with Sturge-Weber syndrome (SWS) will be tested; this new imaging approach, that can create multiple types of MR images in about 5 minutes, without contrast administration (and sedation even in young children), can be also readily applied in other pediatric brain disorders in the future. The investigators will also study how advanced MRI, including susceptibility-weighted and diffusion tensor imaging can detect detailed signs of brain vascular and neuronal reorganization that helps improve neurological and cognitive outcome of children and young adults with SWS, who could benefit from targeted interventions in the future to minimize neurocognitive deficits in affected patients. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | February 28, 2025 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 3 Months to 30 Years |
Eligibility | Inclusion Criteria: 1. Subjects with Sturge-Weber syndrome (SWS): 1. Age 3 months - 30 years; 2. Presence of a facial port-wine birthmark (PWB) indicating a risk for SWS and/or evidence of SWS brain involvement based on the presence of one or more intracranial SWS brain abnormalities from previous clinical imaging (MRI or computed tomography) scan(s) with or without a facial PWB. SWS brain abnormalities can include both brain vascular and/or parenchymal abnormalities (including atrophy, calcification, etc.); 3. In children who will undergo formal neuropsychology testing including detailed language testing (age 3 years and above): proficiency of English language. 2. Healthy control subjects: 1. Age 3 years - 30 years; 2. No history of neurological or psychiatric disorder Exclusion Criteria: For all subjects: 1. Metal in the head or mouth that would preclude safe, artifact-free MRI scanning; or any other metal or electronic device contraindicated for MRI scanning. 2. History of severe claustrophobia, precluding staying still in the scanner for up to 30 minutes. 3. Pregnancy (pregnant women will be scheduled for the study after delivery). For SWS subjects, who will receive MRI contrast material, additional exclusion criteria: 1. History of sensitivity to MRI contrast material; 2. History of renal disease that would preclude safe administration of MRI contrast material |
Country | Name | City | State |
---|---|---|---|
United States | Wayne State University / Children's Hospital of Michigan | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Wayne State University | National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of detection of Sturge-Weber syndrome brain involvement by a novel fast magnetic resonance imaging (MRI) approach as compared to standard MRI. | Presence (score 1) vs. absence (score 0) of SWS brain abnormalities in each of 8 cerebral lobes using fast MRI compared with the same scores obtained from standard MRI, obtained in the same imaging session, as the ground truth. | During procedure | |
Primary | Correlation of enlarged cerebral deep vein scores, measured by magnetic resonance imaging (MRI), with full scale IQ acquired within 1 day. | Full scale IQ (normal mean: 100, standard deviation: 15) will be determined and its correlation with enlarged deep vein scores (range: 0-12, 0 indicating no enlarged deep veins, 12 indicating the most extensive enlarged deep veins) measured by MRI calculated. | 1 day | |
Primary | Correlation of diffusion tensor imaging (DTI) brain connectivity score with verbal IQ acquired within 1 day. | Verbal IQ (normal mean: 100, standard deviation: 15) will be determined by neuropsychology evaluation and correlated with DTI brain connectivity scores (range: 0-1, 0 indicating no connectivity, 1 indicating the strongest connectivity) measured by MRI. | 1 day | |
Primary | Correlation of diffusion tensor imaging (DTI) brain connectivity score with non-verbal IQ acquired within 1 day. | Non-verbal IQ (normal mean: 100, standard deviation: 15) will be determined by neuropsychology evaluation and correlated with DTI brain connectivity scores (range: 0-1, 0 indicating no connectivity, 1 indicating the strongest connectivity) measured by MRI. | 1 day | |
Secondary | Correlation of enlarged deep vein scores determined by magnetic resonance imaging (MRI) with motor scores acquired within 1 day. | Motor scores (normal mean: 100, standard deviation: 15), determined during neuro-psychology evaluation, will be correlated with enlarged deep vein scores (range: 0-12, 0 indicating no enlarged deep veins, 12 indicating the most extensive enlarged deep veins) determined by MRI. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04717427 -
Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome
|
||
Active, not recruiting |
NCT01425944 -
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
|
||
Completed |
NCT04447846 -
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
|
Phase 2 | |
Completed |
NCT05495269 -
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
|
Phase 2 | |
Completed |
NCT01345305 -
Biomarker Development in Sturge-Weber Syndrome
|
||
Withdrawn |
NCT04344626 -
Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery
|
N/A | |
Completed |
NCT03047980 -
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT04999618 -
A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology
|
Phase 4 | |
Completed |
NCT02332655 -
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
|
Phase 1/Phase 2 |